理中汤加味联合美沙拉嗪治疗轻度活动期克罗恩病的临床观察 [中文引用][英文引用]

 [摘要] 目的：探讨理中汤加味联合美沙拉嗪治疗轻度活动期克罗恩病的临床疗效。方法：纳入2019年1月至2022年1月大庆市中医医院收治的100例轻度活动期克罗恩病患者，按照随机字母表法分为对照组(n=50)和试验组(n=50)。对照组采用美沙拉嗪治疗，试验组在对照组治疗基础上联合理中汤加味治疗。比较两组患者治疗前后中医证候积分、克罗恩病活动指数(CDAI)评分和克罗恩病内镜下严重指数(CDEIS)评分、炎性因子(IL-6、TNF-α)水平、免疫功能指标(CD3+、CD4+、CD4+/CD8+)、不良反应发生率。 结果：对照组和试验组的一般基数资料(性别、年龄、BMI、病程、CDAI评分)比较差异无统计学意义(P＞0.05)；试验组的总有效率高于对照组 (P＜0.05)；治疗后两组患者的CDAI和CDEIS评分，血清IL-6、TNF-α、CD3+、CD4+、CD4+/CD8+水平均下降，且试验组均低于对照组 (P＜0.05)；两组治疗期间的不良反应总发生率，差异无统计学意义(P＞0.05)。结论：理中汤加味联合美沙拉嗪治疗轻度活动期克罗恩病的疗效显著，能有效缓解轻度活动期克罗恩病患者的临床症状，减轻炎症反应。

 [Abstract]  Objective  To investigate the clinical efficacy of Jiawei Lizhong Decoction combined with mesalazine in the treatment of mild active Crohn's disease. Methods  A total of 100 patients with mild active Crohn's disease admitted to Daqing Traditional Chinese Medicine Hospital from January 2019 to January 2022 were included, and all patients were divided into control group (n=50) and observation group (n=50) according to the randomized alphabetical method. The control group was treated with mesalazine, and the experimental group was treated with Jiawei Lizhong Decoction on top of the treatment in the control group. The Chinese medicine evidence score, Crohn's disease activity index (CDAI) score and Crohn's disease endoscopic index of severity (CDEIS) score, inflammatory factors (IL-6, TNF-α) levels, immune function indexes (serum CD3+, CD4+, CD4+/CD8+), and incidence of adverse reactions were compared before and after treatment in the two groups. Results  There were no statistically significant differences in the general baseline informations (gender, age, BMI, disease duration, CDAI score) between the control and observation groups (P>0.05). The overall effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the CDAI and CDEIS scores and the serum IL-6, TNF-α, CD3+, CD4+ and CD4+/CD8+levels of patients in both groups decreased, and the experimental group was lower than the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion   Jiawei Lizhong Decoction combined with mesalazine is effective in the treatment of mild active Crohn's disease, which can effectively relieve the clinical symptoms and reduce the inflammatory response in patients with mild active Crohn's disease.